Search Results
Dec 08, 2025, 14:45 ET Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study
either non-specific or typical for patients with GT, with a single related serious adverse event (grade 2 DVT) occurring at the highest dose level (0.9 mg/kg). Anti-drug antibodies impacting PK/PD were observed in five participants; however, titers resolved in one participant with continued dosing, and no
More news about: Hemab Therapeutics
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Elacestrant 345 mg QD+ Everolimus 7.5mg QD(n=50)Elacestrant 345 mg QD
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
Elacestrant 345 mg QD+ Everolimus 7.5mg QD(n=50)Elacestrant 345 mg QD
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
greater than 140 mg BID. Little to no drug accumulation was observed, and CYP3A4 inhibitor azoles did not have a significant impact on exposure.In patients with KMT2Ar, dose optimization of 200, 300, and 400 mg BID is complete, and the RP2D has been determined as 300 mg BID. At RP2D, in
More news about: Sumitomo Pharma America
Dec 08, 2025, 11:00 ET Medical Cannabis Program Reduces Opioid Use
daily opioid dose equivalent to 73.3 mg of morphine. Over the 18-month follow-up period, that average daily dose fell to 57 mg, a 22% reduction.More specifically, those participants who received a 30-day supply of medical cannabis used the equivalent of 3.5 fewer mg of morphine per day than those who
More news about: Montefiore Health System
Dec 08, 2025, 11:00 ET El Programa de Cannabis Medicinal reduce el consumo de opioides
opioides equivalente a 73.3 mg de morfina. Durante el periodo de seguimiento de 18 meses, esa dosis diaria se bajó a 57 mg, una reducción del 22 %.Más concretamente, los participantes que recibieron un suministro de cannabis medicinal para 30 días consumieron una media de 3.5 mg menos de morfina al día
More news about: Montefiore Health System
Dec 08, 2025, 10:30 ET Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
with an attenuated course of standard dose (SD) decitabine and cedazuridine (DEC-C). Patients received 10 mg of oral decitabine and 100 mg cedazuridine for five days or 35 mg decitabine and 100 mg cedazuridine for three days. Patients were treated a median of 8.8 months, with patients in the LD arm receiving
More news about: Taiho Oncology
Dec 08, 2025, 09:05 ET CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
Details: Product: Caldolor® (ibuprofen) InjectionJ-Code: J1741 – Injection, ibuprofen, 100 mgStatus: Now associated with reimbursement price"With Caldolor now linked to an established reimbursement price, healthcare
More news about: Cumberland Pharmaceuticals Inc.
Dec 08, 2025, 09:00 ET Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
spikes above the healthy range and an average glucose reduction of 2 mg/dL compared to days without protein supplementation. Among those with obesity, the benefit was greater: 18% lower odds of glucose spikes above the healthy range and a 3 mg/dL reduction in average glucose. Given that past research shows
More news about: Abbott
Dec 08, 2025, 08:30 ET Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer's Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)
Participants with mild-to-moderate AD, defined by a standardized mini mental status exam (MMSE) score between 16 and 26, were given Tazbentetol (300mg or 150mg) daily for up to 24 weeks, beginning with a four-week placebo-controlled period. The study's primary endpoints included SMMSE, Clinical Dementia
More news about: Spinogenix
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
– 24.0 mg/kg QW). No dose-limiting toxicities (DLTs) were observed, and the maximum tolerated dose (MTD) was not reached.All treatment-related adverse events were Grade 1-2, confirming a cytopenia-sparing safety profile.CD47 receptor occupancy (RO) reached ≥ 75-85% at 1.2 mg/kg and
More news about: HanchorBio Inc.
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
seizures.1,2Phase 3 study resultsPatients treated with fenfluramine (n=42) (0.7mg/kg/day, maximum 26 mg/day) experienced a median reduction of 47.6% in CMSF from baseline, compared with a 2.8% reduction for placebo (n=44) (p<0.001).1
More news about: UCB
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
tablets 1 mg once-daily and then increased the dose in a step-wise approach at one-week intervals to their final randomized target dose of 20 mg (via steps at 1 mg, 2 mg, 5 mg, 10 mg and 15 mg), 40 mg (via steps at 1 mg, 2 mg, 5 mg, 10 mg and 20 mg) or 60 mg (via steps at 1 mg, 2 mg, 5 mg, 10 mg, 20 mg and
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
uncontrolled seizures.1Phase 3 study resultsPatients treated with fenfluramine (n=42) (0.7 mg/kg/day, maximum 26 mg/day) experienced a median reduction of 47.6% in CMSF from baseline, compared with 2.8% for placebo (n=44) (p<0.001).1 This translated
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
uncontrolled seizures.1Phase 3 study resultsPatients treated with fenfluramine (n=42) (0.7 mg/kg/day, maximum 26 mg/day) experienced a median reduction of 47.6% in CMSF from baseline, compared with 2.8% for placebo (n=44) (p<0.001).1 This translated
More news about: UCB
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) for 3 consecutive days, while 2 patients received reduced-dose lymphodepletion. CT0596 was administered at dose levels of 1.5×10⁸
More news about: CARsgen Therapeutics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) for 3 consecutive days, while 2 patients received reduced-dose lymphodepletion. CT0596 was administered at dose levels of 1.5×10⁸
More news about: CARsgen Therapeutics
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.About Chronic Lymphocytic Leukemia/Small
More news about: Eli Lilly and Company
Dec 07, 2025, 15:00 ET Replicor publishes data from its compassionate access program in HBV/HDV
This compassionate access program, initiated with Dr. Marc Bourlière in France, deployed REP 2139-Mg in patients with chronic HBV / HDV infection who had failed on bulevirtide or lonafarnib and who had cirrhosis or decompensated cirrhosis. The access
More news about: Replicor Inc.
Dec 07, 2025, 09:30 ET Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
the 750 mg dose group.For evaluable transfusion dependent (TD) patients (≥16 weeks follow up) at dose levels of at least 500 mg QD and higher, 6/18 (33%) patients achieved durable red blood cell transfusion independence (RBC-TI) of >8 weeks [500 mg QD (1/3), 750 mg QD (2/5), 500/250 mg QD (1/5),
More news about: Rigel Pharmaceuticals, Inc.
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
low as 0.03 mg/kg.In a humanized mouse lupus model, ORN-252 showed robust B cell depletion with concurrent reduction in dsDNA titers in contrast to rituximab.Treatment with ORN-252 led to complete peripheral and splenic B cell depletion in NHP at doses as low as 0.1 mg/kg.CAR+
More news about: Orna Therapeutics
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
generating functional CAR-T cells in vivo in the absence of cytotoxic conditioning.Patient 1 received three doses of 0.5 mg, and Patient 2 received four doses of 1.5 mg. GT801 was generally well tolerated. Both patients showed high CAR expression within circulating T cells. Durable and repeatable
More news about: Vivacta Biotechnology Co., Ltd.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
was reported in 36% (102/285) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 93% (265/285) of patients. Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 94% (267/285) of patients treated. Fifty-six percent
More news about: Johnson & Johnson
Dec 05, 2025, 11:24 ET Myasthenia Gravis Foundation of America (MGFA) Delivers a Lexicon of Myasthenia Gravis Terminology to Help Patients Better Understand MG
https://myasthenia.org/wp-content/uploads/2025/11/MGFA-Lexicon.pdfThis digital MG Lexicon defines terms related to diagnosing, living with, and managing MG to make it easier to understand complex words, phrases, and concepts as part of MG care. Patients can empower themselves to accurately describe their symptoms
More news about: Myasthenia Gravis Foundation of America, Inc.
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
of diazepam nasal spray (based on patient age and weight (0.5 mg/kg)), similar to observations in patients aged 6-65 years in the separate long-term safety study of diazepam nasal spray. These findings support the effectiveness of the 0.5 mg/kg dose in patients aged 2-5 years.Interval
More news about: Neurelis, Inc.